The companies at the frontier of artificial intelligence should be ready to slow down, one of the fastest-moving among them says. Anthropic, the maker of the Claude chatbot, has claimed AI systems may ...
Najat Khan looks at successful platform companies like Vertex, Regeneron and Alnylam and sees a path for Recursion to join them—if the company stays disciplined. (Recursion Pharmaceuticals) Chris ...
This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. logos of OpenAI There’s interesting news coming from Sam Altman’s empire, a firm known for ...
Add Yahoo as a preferred source to see more of our stories on Google. logos of OpenAI Anadolu via Getty Images There’s interesting news coming from Sam Altman’s empire, a firm known for innovating as ...
Forbes contributors publish independent expert analyses and insights. John Sviokla covers GenAI/AI's impact on commerce and society. This voice experience is generated by AI. Learn more. This voice ...
Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Spencer Judge discusses the architectural ...
When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...
After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results